You’re free now, FDA lifts clinical hold on Arbutus Biopharma’s AB-101 drug

Landon Capital News

Arbutus Biopharma Corporation (ABUS) announced that the U.S. Food and Drug Administration has lifted a clinical hold on the Investigational New Drug application for AB-101, an oral PD-L1 inhibitor being developed for chronic hepatitis B virus infection. The company said it is evaluating next steps for continued development of the drug.

AB-101 is designed to activate patients’ hepatitis B virus-specific immune response by inhibiting PD-L1. The drug has completed a Phase 1a/1b clinical trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending oral doses in healthy subjects and patients with chronic HBV infection.

About Landon Capital
Landon Capital Inc. is a media company that wholly owns subsidiaries Landon Capital Management LLC and Landon Capital News. Landon Capital News distributes economic, and political news in over 176 countries. Landon Capital News provides an in depth and simplistic look at financial, economic, and political news, as it is happening. We also provide our viewers with in-depth analysis on various companies and political news that directly correlate to economics. We bridge the gap of information between the investor and the markets, sectors and industries that they invest. For more information, please contact us at info@landoncapital.net or 404-995-6671 or visit https://landoncapital.net.

Safe Harbor Statement
This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Landon Capital received no direct compensation related to this release. This release contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Actual results may differ materially from those stated or implied in.